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doi: 10.5694/mja15.00174ResearchSafety of opioid patch initiation in Australian
residential aged careAbstractpioid analgesics are recom-
mended for the treatment ofObjective: To explore opioid use by aged care facility residents before
and after initiation of transdermal opioid patches.
Design: A cross-sectional cohort study, analysing pharmacy data on
individual patient supply between 1 July 2008 and 30 September 2013.
Setting: Sixty residential aged care facilities in New South Wales.
Participants: Residents receiving an initial opioid patch during the
study period.
Main outcome measure: The proportion of residents who were opioid-
naive in the 4 weeks prior to patch initiation was determined. In addition, the
patch strength at initiation and the daily dose of transdermal patches and
of additional opioids 1 month after initiation were determined.
Results: An opioid patch was initiated in 596 of 5297 residents (11.3%:
2.6% fentanyl, 8.7% buprenorphine) in the 60 residential aged care
facilities. The mean age at initiation was 87 years, and 74% of the recipients
were women. The proportion of recipients who were opioid-naive before
patch initiation was 34% for fentanyl and 49% for buprenorphine. Most
were initiated at the lowest available patch strength, and the dose was
up-titrated after initiation. Around 15% of fentanyl users and 10% of
buprenorphine users needed additional regular opioids after patch
initiation.
Conclusions: The results suggest some inappropriate initiation of opioid
patches in Australian residential aged care facilities. Contrary to best
practice, a third of residents initiated on fentanyl patches were opioid-
naive in the 4 weeks before initiation.Ocancer pain and for short-
term treatment of moderate to se-
vere acute pain.1,2 The number of
opioid prescriptions in Australia
reimbursed by the Pharmaceutical
Benefits Scheme increased from 2.4
million in 2002 to 7.0million in 2007.3
Much of this increase is probably
driven by the increased administra-
tion of opioids for chronic non-cancer
pain,3,4 but such use remains contro-
versial, especially in older people, as
they are more susceptible to adverse
drug events.5-7
Transdermal opioid patches have
been designed to provide long-lasting
therapy forpatientswithchronicpain.
Two opioids are available for admin-
istration via transdermal patches:
fentanyl and buprenorphine. Fenta-
nyl patches have a duration of action
of 3 days, while buprenorphine
patches are active for 7 days.1 In
addition to an extended duration of
action, transdermal opioids also have
a slower onset of action,making them
unsuitable for the management of
acute pain.1
For chronic, non-cancer pain, Austra-
lianguidelines recommendastepwise
approach, with an initial trial of non-
opioid analgesics followed by weak
opioids if simple analgesics are not
effective.8,9 Oral morphine or oxyco-
done and transdermal buprenorphine
are considered first-line options for
chronic non-cancer pain. For frail
or older patients, a low dose of
immediate-release opioid may be
used to assess responsiveness;8,9 once
initial dosing requirements have been
determined, sustained-release prepa-
rations, including transdermal bup-
renorphine patches, may increase
patient compliance, as the frequency
of administration is reduced com-
pared with other dosing forms.7,10
Potent opioids, such as fentanyl, are
only recommended for patients with
chronic severe and disabling pain
who exhibit tolerance for opioids anddo not respond to non-narcotic anal-
gesics.1,10,11 The margin between the
therapeutic and toxic doses of fenta-
nyl is small, and it has been asso-
ciated with a number of fatalities
in opioid-naive patients.12,13 Guide-
lines recommend that fentanyl is
most appropriate in the treatment of
opioid-tolerantpalliativecarepatients
and patients with cancer.8 Fentanyl
patches should not be used in opioid-
naive patients, and the equianalgesic
opioid dose should be determined
before initiation of the patch.8,11
Given the difficulties with the dose
titration of transdermal buprenor-
phine preparations and concerns
about the safety of fentanyl in opioid-
naive patients, the use of transdermal
preparations in older patients should
be limited to opioid-tolerant patients
with stable opioid requirements.
The aim of our study was to explore
analgesic use before and after the
initiation of transdermal opioid
patches in residents of AustralianMJA 203 (7)aged care facilities. The specific
objectives were to determine the
proportion of people who were
opioid-naive or opioid-tolerant prior
to initiation of the transdermal
product, and to determine how initi-
ation of transdermal opioids affected
the use of other opioids.
Methods
Data source
De-identified pharmacy data on all
medicines supplied in dose adminis-
trationaids to 60 residential aged care
facilities in New South Wales during
the period 1 July 2008 to 30
September 2013 were analysed. All
medications supplied to residents in
these facilities, including over-the-
counter products, must be packed in
a dose administration aid that com-
prises blisters containing all medica-
tions administered at a single dosing
point, enabling assessment of inten-
ded co-administration. The blistersj 5 October 2015 298.e1
1 Characteristics of aged care residents in whom transdermal opioid
patches were initiated
Fentanyl
initiators
Buprenorphine
initiators P
Number 137 459
Mean age at initiation, years (SD) 86 (8.4) 87 (7.6) 0.148*
Sex
Male 30 (22%) 126 (27%) 0.194†
Female 107 (78%) 333 (73%)
* Student t test. † c2 test.u
298.e2
Researchalso reflect any changes made to any
medicine in the weekly supply, so
that all changes are identified at the
time they occur.
The database therefore provides
complete medication records for all
residents, including a unique resi-
dent identifier, sex, date of birth, date
of death, generic and brand medica-
tion names, duration for which each
medicine was dispensed, strength,
dose anddosage instructions for each
medicine, and pro re nata use (“as
needed”).
Analgesic medicines included in
the analyses
Included in the analyses were
narcotic analgesics (opioids: codeine,
codeine with paracetamol, metha-
done, morphine, hydromorphone,
oxycodone, tramadol, pethidine,
dextro-propoxyphene, fentanyl and
buprenorphine), simple analgesics
(paracetamol) and oral non-steroidal
anti-inflammatory drugs (NSAIDs:
including COX-2 selective inhibitors,
but excluding topical preparations).
Patch initiation and previous
analgesic use
A cross-sectional cohort study was
undertaken to determine the use of
analgesics in the 4 weeks prior to
initiation of fentanyl and buprenor-
phine transdermal patches. Incident
opioid patch use was defined as the
first (index) dispensing of a fentanyl
or buprenorphine patch between 1
July 2008 and 30 September 2013,
with no use during the previous year.
Patients who received their index
opioid patch at the time of their
admission to the residential aged care
facility were excluded, because their
analgesic use in the previous year
could not be established. The pro-
portions of residents initiated on
patches who were naive to all anal-
gesics or to opioids and those who
were opioid-tolerant were deter-
mined. Opioid-naive users were
defined as those who had not
received an opioid analgesic (but
may have received other simple or
NSAID analgesics) in the 4 weeks
prior to their first patch. Opioid-
tolerant residents were those who
had received an opioid, either regu-
larly or pro re nata, in the 4-weekMJA 203 (7) j 5 October 2015period before patch initiation. The
initiation strength of the patches was
also determined.
Patch initiation and opioid use
The proportion of residents starting
on a fentanyl or buprenorphine patch
who received opioids (regularly or
pro re nata) during the 30 days before
or after patch initiation was calcu-
lated as a percentage of the entire
sample of patch initiators.
Daily doses of regular opioids other
than patches, when used concur-
rently with the patches, were calcu-
lated for the 30 days before and the 30
days after patch initiation. The dose
of each generic agent in combination
products was determined separately.
The daily dose of each medicine on a
given day was calculated from the
product of the strength of the medi-
cine and the dosage instructions (eg,
oxycodone 10mg twice a day¼ daily
dose of 20 mg). Opioid strengths,
including transdermal patches, were
converted to oral morphine equiva-
lents using opioid equianalgesic con-
version ratios.14Transdermal fentanyl
was converted to the lowest daily oral
morphine dose in the range provided
(ie, 12 mg/h fentanyl to 30 mg
morphine, and 25 mg/h fentanyl to 60
mg morphine).
The mean daily dose was calculated
for each patch and for the opioids in
total. For the dose calculation, as-
needed use was excluded because of
the lack of information about the
actual daily usage.
Statistical analyses
The Pearson c2 test and the Student
t test were applied to compare cohortcharacteristics and proportions.
Linear regression trend lines were
fitted to the trends in daily dose after
initiation of the patches. Analyses
were performed with the SAS 9.4
statistical package (SAS Institute).
Ethics
This study was approved by the Syd-
ney Local Health District Human
Research Ethics Committee, Concord
RepatriationGeneralHospital (CH62/
6/2010-49 HREC/10/CGRH/57).
Results
Patch initiation and previous
analgesic use
The dataset included 5297 residents
who received at least one medication
between 1 July 2008 and 30 Sep-
tember 2013. Fentanyl patches were
initiated in 137 individuals (2.6%)
and buprenorphine patches in 459
(8.7%). The mean age was similar in
both treatment groups, and74%were
women (Box 1).
More than a third (34%, 46 of 137) of
residents who began using a fentanyl
patch and almost half (49%, 224/459)
of those who began using a bupre-
norphine patch were opioid-naive
(Box 2).
Of the opioid- or analgesic-naive
residents who received a fentanyl or
buprenorphine patch, 87% (46 of 53)
and 92% (229 of 250), respectively,
commenced on the lowest available
strength (12 mg/h fentanyl; 5 mg/h
buprenorphine). Further, more than
80% of those who had received opi-
oids before a transdermal patch were
also started on the lowest strength
2 Analgesic use prior to patch initiation
* P < 0.05 for difference between fentanyl and buprenorphine initiators (c2 test).u
Researchdose (69 of 84 for fentanyl; 168 of 209
for buprenorphine). No opioid- or
analgesic-naive residents who re-
ceived a fentanyl patch were initiated
on the highest strength (50 mg/h), and
only three of the 250 opioid- or
analgesic-naive patients who received
a buprenorphine patch were initiated
on the highest strength (20 mg/h).3 Daily dose of fentanyl or buprenorphine, presented as morphine
equivalents*
* As-needed opioids were excluded from analysis because of the lack of information on the dose
administered.uPatch initiation and opioid use
After patch initiation, residents
receiving fentanyl and buprenor-
phine were up-titrated to higher
doses (Box 3).
Just under 30% of fentanyl initiators
had used regular opioids (Box 4) and
just under 25% had been using as-
needed opioids in the 4 weeks before
patch initiation (Box 5). About 20% of
buprenorphine initiators had previ-
ously used regular opioids (Box 4)
and about 18% had received them as
needed (Box 5). Most residents were
receiving oral formulations. The
most commonly used opioids before
patch initiation were oxycodone and
codeine.
After patch initiation, the propor-
tion of those who continued to
receive regular opioids concur-
rently with their patch was about
15% (21 of 137) for fentanyl users
and 10% (47 of 459) for buprenor-
phine users (Box 4). In residentsreceiving fentanyl, the total daily
dose of regular opioids increased
immediately after patch initiation
and then declined over time; in
residents with a buprenorphine
patch, the total daily opioid dose
increased slightly after patch initi-
ation and then continued to in-
crease over the next 30 days (Box 6).
In both groups, the proportion of
people who received opioids as
needed increased immediately after
patch initiation, but then decreasedby day 30 to 30% (41 of 137) for
fentanyl and to 23% (106 of 459) for
buprenorphine (Box 5).Discussion
The availability of transdermal opioid
formulations provides increased
analgesic options for themanagement
of chronicpain.However, initiationof
transdermal opioids requires addi-
tional caution with the appropriate
choice of agent and dose titration,
especially in older patients. Our re-
sults indicate that fentanyl patches
were initiated in 2.6% of aged care
residents, andbuprenorphinepatches
in 8.7%. While the use of transdermal
buprenorphine is recommended for
the management of chronic pain,
when commencing opioids in older
patients a low-dose immediate-
release preparation is recommended
once their opioid requirements have
been ascertained, and the dose
should then be titrated accordingly.8,9
Transdermal fentanyl is not recom-
mended in opioid-naive individuals
because of its high potency. In this
study, a relatively high use of both
fentanyl and buprenorphine patches
in opioid-naive aged care residents
was observed, and this raises safety
concerns.
Fentanyl is a highly potent opioid. It
is not appropriate for opioid-naiveMJA 203 (7) j 5 October 2015 298.e3
4 Proportion of residents receiving regular opioids before and after
patch initiation*
* After-patch initiation use denotes regular opioid use concurrent with transdermal patch use.u
298.e4
Researchpatients because of the risk of
toxicity, including respiratory de-
pression and overdose-related mor-
tality.12,13 The United States Food
and Drug Administration released a
number of safety communications
regarding the dangers of fentanyl
patches in opioid-naive patients.15
In Australia, the Pharmaceutical
Benefits Scheme allows a restricted
benefit for the treatment of chronic
severe disabling pain that does not
respond to non-narcotic analgesics.
In our study, a third of aged care
residentswhowere commenced on a5 Proportion of residents receiving a
patch initiation*
* After-patch initiation use denotes as-needed op
use.u
MJA 203 (7) j 5 October 2015fentanyl patch were opioid-naive.
Our findings in residents who had
previously used opioids are similar
to those of a Dutch study which
reported that 60% of patients who
began using fentanyl patches had
previously used other opioids.16 If
fentanyl patches are to be used in
opioid-naive patients with cancer
pain, they should not be initiated at
doses greater than 25 mg/h.11 We
found that no opioid- or analgesic-
naive patients were initiated with
fentanyl patches at doses higher
than this.s-needed opioids before and after
ioid use concurrent with transdermal patchCommencement of anyopioid in older
patients requires a “start low and go
slow” approach.7 A low initial opioid
dose followed by cautious upward
titration to achieve adequate analgesia
is the strategy recommended by the
current Australian guidelines.8,9 One
limitationof transdermalpatches is the
lack of flexibility in dosing titration.17
Use of transdermal buprenorphine in
opioid-naive aged care residents,
although pharmacologically appro-
priate for managing chronic pain,
does not allow adequate titration
and may result in over- or under-
dosing. In our study, doses of regu-
lar concurrent opioids continued to
increase after initiation of trans-
dermal buprenorphine in aged care
residents, suggesting that under-
dosing and inadequate pain relief
may be problems.
Similar studies that have explored
prior opioid use in people first
prescribed transdermal buprenor-
phine reported much higher pro-
portions of opioid-tolerant patients.
In our aged care residents, 45% of
patients prescribed a buprenor-
phine patch were opioid-tolerant
prior to initiation. A US study
found that 92% of patients
commencing buprenorphine were
opioid-tolerant,18 while a German
postmarketing surveillance study
found that 70% of new users were
opioid-tolerant.19 However, these
studies were not conducted in res-
idential aged care settings.
Although transdermal opioid patches
are being prescribed for opioid-naive
aged care residents, it appears that
the “start low and go slow” adage is
being followed. The adverse effects of
opioids are dose-related2; excessive
daily opioid doses for non-malignant
pain is strongly associated with
opioid-related mortality.6 Lower
starting doses and slow dose titration
need to be considered, to take into ac-
count the patient’s individual toler-
ance.7 We found that most residents
were starting at the lowest doses of
each patch type and the dosewas then
slowly up-titrated, consistent with
findings in primary care in the United
Kingdom.20
Breakthrough pain is an exacerba-
tion of otherwise well managed
6 Daily dose of regular opioids, presented as morphine equivalents*
* After-patch initiation use denotes as-needed opioid use concurrent with transdermal patch use.
As-needed opioids have been excluded from analysis because of the lack of information on
administered dose.u
Researchchronic pain. Guidelines indicate
that if transdermal opioid patches
are initiated, additional, immediate-
release analgesics may be co-
dispensed in the case of break-
through pain.1 Non-opioid analgesic
options may be considered in people
without cancer, while short-action
opioids should be used as needed in
those with cancer.2,10 Even though
opioid use decreased after patch
initiation, we found that 15% of fen-
tanyl users and 10% of buprenor-
phine users were still taking regular
opioids concurrently with their
patches. This is similar to a post-
marketing surveillance study which
reported that 14% of patients neededconcomitant opioids after starting
buprenorphine therapy.19 We found
that the required doses of regular
concurrent opioids decreased after
patch initiation in those receiving
fentanyl, while they increased in
those receiving buprenorphine.
Further, a third of fentanyl users and
a quarter of buprenorphine users
received concomitant oral or paren-
teral opioids on an as-needed basis 1
month after patch initiation.Study strengths and limitations
The dataset used in this study pro-
vided a complete medication history
for each resident in 60 aged care facil-ities. All medications, including those
purchased over the counter, are
captured in the dataset. This is impor-
tant, asmanyparacetamol andNSAID
preparations are available over the
counter inAustralia.While a complete
medication history was available for
each resident, the dataset does not
contain any clinical information, such
as indication, so that it is possible that
some of the analgesics were used for
acute or cancer pain, or for palliative
care. Problems of safety and adequate
pain control in opioid-naive patients
are not related to the indication for
which they are taken, so that the
absence of data on indication is un-
likely to affect our results. A second
limitation was the lack of dosing
information for as-needed medicines.
As-needed opioids were included in
all our analyses, except when calcu-
lating the total daily opioid dose.Conclusion
Our results suggest a certain degree
of inappropriate initiation of opioid
patches in Australian residential
aged care. Contrary to best practice, a
third of residents commencing fen-
tanyl patches and almost half of those
commencing buprenorphine patches
were opioid-naive in the 4 weeks
before initiation of the transdermal
patch.
Acknowledgements: We acknowledge Mr Gerard
Stevens, managing director of Webstercare, for his
contribution to data collection and provision.
Competing interests: No relevant disclosures.n
ª 2015 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights
reserved.MJA 203 (7) j 5 October 2015 298.e5
298.e6
Research1 Pharmaceutical Society of Australia, morphine, oxycodone). Pain Pract cancer/docs/Opioid_Conversion.pdf
Australasian College of General
Practitioners, Australasian Society of
Clinical and Experimental
Pharmacologists and Toxicologists.
Australian medicines handbook 2010.
Adelaide: AMH, 2010.
2 Macintyre PE, Scott DA, Schug SA,
et al. Acute pain management:
scientific evidence. 3rd edition.
Melbourne: Australian and New
Zealand College of Anaesthetists and
Faculty of Pain Medicine, 2010. http://
sydney.edu.au/medicine/pmri/pdf/
Acute-pain-management-scientific-
evidence-third-edition.pdf (accessed
Jul 2015).
3 Leong M, Murnion B, Haber P.
Examination of opioid prescribing in
Australia from 1992 to 2007. Intern Med
J 2009; 39: 676-681.
4 Boudreau D, Von Korff M, Rutter C,
et al. Trends in long-term opioid
therapy for chronic non-cancer pain.
Pharmacoepidemiol Drug Saf 2009; 18:
1166-1675.
5 Van Ojik A, Jansen P, Brouwers J, et al.
Treatment of chronic pain in older
people: evidence-based choice of
strong-acting opioids. Drugs Aging
2012; 29: 615-625.
6 Gomes T, Mamdani M, Dhalla I, et al.
Opioid dose and drug-related mortality
in patients with nonmalignant pain.
Arch Intern Med 2011; 171: 686-691.
7 Pergolizzi J, Böger RH, Budd K, et al.
Opioids and the management of
chronic severe pain in the elderly:
consensus statement of an
International Expert Panel with focus
on the six clinically most often used
World Health Organization Step III
opioids (buprenorphine, fentanyl,
hydromorphone, methadone,MJA 203 (7) j 5 October 20152008; 8: 287-313.
8 Analgesic Expert Group. Therapeutic
guidelines: analgesics. Version 5.
Melbourne: Therapeutic Guidelines,
2007.
9 Royal Australian College of Physicians.
Prescription opioid policy: improving
management of chronic non-malignant
pain and prevention of problems
associated with prescription opioid use.
Sydney: RACP, 2008. http://www.fpm.
anzca.edu.au/resources/professional-
documents/documents/Prescription%
20Opioid%20Policy.pdf (accessed Jul
2015).
10 NPS MedicineWise. Opioids — a
planned approach to prescribing
opioids for persistent non-cancer pain.
MedicineWise News, 1 Jun 2010. http://
www.nps.org.au/publications/health-
professional/nps-news/2010/nps-
news-69 (accessed Jul 2015).
11 NPS MedicineWise. Generic brand of
fentanyl patches (Denpax) PBS listed.
NPS RADAR, 1 Aug 2011. http://www.
nps.org.au/publications/health-
professional/nps-radar/2011/august-
2011/brief-item-generic-fentanyl-
patches (accessed Jul 2015).
12 Paparella S. A serious threat to patient
safety: the unintended misuse of
fentanyl patches. J Emerg Nurs 2013;
39: 245-247.
13 Grissinger K. Inappropriate prescribing
of fentanyl patches is still causing
alarming safety problems. P&T 2010;
35: 653-654. http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3008378/
(accessed Jul 2015).
14 Government of Western Australia,
Department of Health. Opioid
conversion guide. http://www.
healthnetworks.health.wa.gov.au/(accessed Jul 2015).
15 US Food and Drug Administration. FDA
requiring colour changes to Duragesic
(fentanyl) pain patches to aid safety —
emphasizing that accidental exposure
to used patches can cause death
[media release]. Sep 2013. http://www.
fda.gov/Drugs/DrugSafety/ucm368
902.htm (accessed Jul 2015).
16 Breekveldt-Postma N, Penning-van
Beest F, Hering R. Utilisation pattern of
fentanyl transdermal system in the
Netherlands. Pharmacoepidemiol Drug
Saf 2005; 14: 129-134.
17 Ball A, Smith K. Optimizing
transdermal drug therapy. Am J Health
Syst Pharm 2008; 65: 1337-1346.
18 Pergolizzi J, Ben-Joseph R, Chang C,
et al. US practitioner prescribing
practices and patient characteristics of
those newly treated with a
buprenorphine transdermal patch
system. Curr Med Res Opin 2014; 30:
1579-1587.
19 Griessinger N, Sittl R, Likar R.
Transdermal buprenorphine in clinical
practice — a post-marketing
surveillance study in 13 179 patients.
Curr Med Res Opin 2005; 21: 1147-1156.
20 Gallagher A, Leighton S, van Staa T.
Utilization characteristics and
treatment persistence in patients
prescribed low-dose buprenorphine
patches in primary care in the United
Kingdom: a retrospective cohort study.
Clin Ther 2009; 31: 1707-1715.-
